Evidence map›Paper›PMID 40688030›Full record

ReviewInternational journal of pharmaceutics: X2025

Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.

Saber Imani, Samaneh Moradi, Tola Abdulsattar Faraj, Pejman Hassanpoor, Nazanin Musapour, Soran K Najmaldin, Anno Hashm Abdulhamd, Aliasghar Tabatabaei Mohammadi, Chnar Husam Taha, Sargol Aminnezhad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saber ImaniShulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Samaneh MoradiDepartments of Internal Medical, Shiraz University of Medical Sciences, Shiraz, Iran.
Tola Abdulsattar FarajDepartment of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq.
Pejman HassanpoorDepartment of Microbiology, Faculty of Basic Sciences, Rouzbahan Institute of Higher Education, Sari, Iran.
Nazanin MusapourClinical Research Development Center, 5th Azar Medical Center, Golestan University of Medical Sciences, Gorgan, Iran.
Soran K NajmaldinDepartment of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq.
Anno Hashm AbdulhamdDepartment of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq.
Aliasghar Tabatabaei MohammadiSchool of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Chnar Husam TahaDepartment of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil, Iraq.
Sargol AminnezhadDepartment of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles (NPs) are changing the paradigm of precision oncology by providing means for targeted delivery, immune modulation, and personalized therapies for patients. To this end, drug delivery systems (DDS) have improved the precision in precision medicine and improved the design, delivery, and targeting of immune interventions through the use of NPs. This review aims to address the most clinically relevant NP platforms, including lipid (LNPs), polymeric (PNPs), metal-based (MNPs), ceramic (CNPs), carbon-based (CBNs), aptamer conjugated (ANPs), and quantum dots (QDs), and reviewed as potential therapeutic and diagnostic applications and their utility in oncology. Further, we will touch on next-generation systems, including hybrid NPs (HNPs), stimulus-response NPs (SRNPs), and artificial-intelligence (AI) directed NPs (AI-NPs) that are programmable and adaptive with precision-engineered capabilities for cancer vaccinations and immunotherapy. We will discuss how NPs function as a DDS and how these systems facilitate controlled antigen release, better delivery to antigen-presenting cells, and the delivery of neoantigen-based immunotherapies. The ability of NPs to support cell-based therapies, including CAR-T cells, and help overcome multi-drug resistant (MDR) is also explored. Although obstacles remain regarding the development of scalable, safe, and regulatory approved therapies, the ongoing progress in the field of nanomedicine suggests new strategies enabling the delivery of efficient personalized anticancer therapies with clinical benefits for cancer patients.

Indexed as

Drug delivery systemsImmunotherapyNanoparticlesPrecision oncologyVaccine development

Identifiers

PMID40688030
PMCPMC12275137

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.